Literature DB >> 3041387

Cardiovascular drugs in children: angiotensin-converting enzyme inhibitors.

A Schneeweiss.   

Abstract

Angiotensin-converting enzyme inhibitors are potent vasodilators acting by inhibition of production of the vasoconstrictor angiotensin II. In adults, they are used for treatment of systemic hypertension and congestive heart failure and investigated for treatment of primary pulmonary hypertension. In infants and children, saralasin and captopril were found to be useful in treatment of systemic arterial hypertension, especially when associated with high plasma renin activity. Captopril has failed in the treatment of congestive heart failure associated with complex congenital heart diseases and in most cases of primary pulmonary hypertension. It has a clear beneficial effect in coarctation of the aorta and may have such an effect in endomyocardial diseases and ventricular septal defect. In adults, serious side effects have limited the use of captopril. New converting enzyme inhibitors, devoid of a sulfhydryl group, are expected to have a better safety profile.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041387     DOI: 10.1007/BF02083709

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  40 in total

1.  The history and present status of aortic surgery in Japan, particularly for aortitis syndrome.

Authors:  S Kimoto
Journal:  J Cardiovasc Surg (Torino)       Date:  1979 Mar-Apr       Impact factor: 1.888

2.  Use of the oral angiotensin I--converting enzyme inhibitor (captopril) in childhood malignant hypertension.

Authors:  S E Oberfield; D B Case; L S Levine; R Rapaport; W Rauh; M I New
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

3.  Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis.

Authors:  M A Ondetti; N J Williams; E F Sabo; J Pluscec; E R Weaver; O Kocy
Journal:  Biochemistry       Date:  1971-10-26       Impact factor: 3.162

4.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

5.  Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme.

Authors:  J G Collier; B F Robinson; J R Vane
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

6.  Clinical use of captopril in Takayasu's disease.

Authors:  E Grossman; B Morag; N Nussinovitch; H Boichis; A Knecht; T Rosenthal
Journal:  Arch Intern Med       Date:  1984-01

7.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

8.  Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease.

Authors:  A R Sinaiko; B L Mirkin; D A Hendrick; T P Green; R F O'Dea
Journal:  J Pediatr       Date:  1983-11       Impact factor: 4.406

9.  Effective use of captopril in postoperative paradoxical hypertension of coarctation of the aorta.

Authors:  A Casta; V R Conti; A Talabi; B H Brouhard
Journal:  Clin Cardiol       Date:  1982-10       Impact factor: 2.882

Review 10.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

View more
  3 in total

1.  Cough and converting enzyme inhibitors.

Authors:  M G Bianchetti; M Caflisch; O H Oetliker
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

2.  Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block.

Authors:  L Hein; M E Stevens; G S Barsh; R E Pratt; B K Kobilka; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 3.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.